# Schedules of Controlled Substances: Diphenidine Scheduling Update > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/diphenidine-controlled-substance-scheduling-update/ > **Published:** 2026-06-22T14:53:50-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:38:28-04:00 > **Clinical Summary:** Explore the latest diphenidine controlled substance scheduling by the DEA, highlighting regulatory updates and clinical implications of Schedule I placement. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register diphenidineSchedule I controlled substanceDEA scheduling[controlled substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) policyfederal drug regulationDEA drug placementSchedule I classification Clinical Summary The Drug Enforcement Administration has moved to classify diphenidine, a synthetic arylcyclohexylamine dissociative compound, as a Schedule I controlled substance due to its high potential for abuse and lack of currently accepted medical use in the United States. Diphenidine is structurally similar to other dissociative drugs like phencyclidine (PCP) and ketamine but has emerged as a novel psychoactive substance with growing illicit prevalence. This regulatory action addresses [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) concerns related to diphenidine’s abuse potential and its availability as an uncontrolled research chemical, which has complicated clinical and law enforcement response. While diphenidine itself has no established therapeutic application in cannabis or broader pain and psychiatric medicine, this scheduling reflects the broader regulatory environment in which clinicians operate when considering dissociative-based therapeutics, particularly as ketamine and esketamine gain acceptance for treatment-resistant depression and acute suicidality. Clinicians should remain aware that novel synthetic compounds continue to emerge in unregulated markets and may present clinical toxicity issues in patients presenting with substance use complications. Practitioners should stay informed about emerging [drug scheduling](https://cedclinic.com/controlled-substances-rescheduling-2026/) actions to better counsel patients about substance risks and to understand the evolving legal landscape affecting access to evidence-based dissociative therapies. Clinical Perspective 💊 The DEA’s scheduling of diphenidine as a Schedule I controlled substance reflects the regulatory challenge posed by novel synthetic drugs that emerge faster than formal evaluation systems can accommodate. Diphenidine, a dissociative compound structurally similar to PCP and ketamine, carries concerning neurotoxic potential based on limited preclinical data, though clinical experience in humans remains sparse since it primarily circulates through illicit channels. Clinicians should recognize that Schedule I placement does not automatically indicate the drug’s absolute danger relative to scheduled pharmaceuticals, but rather signals lack of accepted medical use and high abuse potential, leaving healthcare providers with minimal evidence base should they encounter acute toxicity cases. In practice, emergency and [addiction medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/) specialists should maintain awareness that novel dissociatives like diphenidine may present with presentations mimicking PCP or ketamine intoxication (agitation, psychosis, dissociation, potential seizures), yet specific antidotes 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Diphenidine+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Diphenidine+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - [Policy Watch: 20 Regulatory Updates — June 21, 2026](https://cedclinic.com/schedules-controlled-substances-placement-june-2026/) - Schedules of [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/): Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I - [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) 📰 Source: [https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i](https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Diphenidine Placement in Schedule I Controlled Substances](https://cedclinic.com/diphenidine-schedule-i-controlled-substance-update/) Detailed update on the DEA’s placement of diphenidine in Schedule I, covering regulatory and clinical perspectives. [Read More](https://cedclinic.com/diphenidine-schedule-i-controlled-substance-update/) Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I Overview of the DEA’s temporary scheduling actions for novel synthetic dissociatives similar to diphenidine. Explore Details DEA Update on Diphenidine Scheduling in Controlled Substances Act Insights into the DEA’s recent scheduling decisions regarding diphenidine and implications for [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). Learn More ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).